Sotabase

Career

· Co-founder, Gruhas2021–
· Co-founder, Zerodha2010–

Publications (9)

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.
Journal of Allergy and Clinical Immunology · 2013
536
cited
Evaluation of inpatient postpartum recovery using the Obstetric Quality of Recovery-10 patient-reported outcome measure: a single-center observational study.
American Journal of Obstetrics & Gynecology MFM · 2020
57
cited
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study
Respiratory Research · 2022
22
cited
Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS)
Clinical and Translational Allergy · 2022
20
cited
Idiopathic pulmonary fibrosis therapy development: a clinical pharmacology perspective
Therapeutic Advances in Respiratory Disease · 2023
9
cited
Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma
2016
1
cited
Recombinant human pentraxin-2 for idiopathic pulmonary fibrosis: Design of STARSCAPE-OLE, a Phase III open label extension study
Idiopathic interstitial pneumonias · 2021
1
cited
Le Fort I Osteotomy with placement of Distractor
2017
Type 2 Biomarkers Define a Prevalent Phenotype in Moderate-to-Severe, Uncontrolled Asthma Patients: A Pooled Analysis from Lebrikizumab All-Comers Phase 2 Trials
2016
Sotabase
Nikhil Kamath | Researcher Profile | Sotabase | Sotabase